HomeCompareTRRTX vs ABBV

TRRTX vs ABBV: Dividend Comparison 2026

TRRTX yields 5.95% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $75.1K in total portfolio value
10 years
TRRTX
TRRTX
● Live price
5.95%
Share price
$11.54
Annual div
$0.69
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.6K
Annual income
$869.58
Full TRRTX calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — TRRTX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRRTXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRRTX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRRTX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRRTX
Annual income on $10K today (after 15% tax)
$505.80/yr
After 10yr DRIP, annual income (after tax)
$739.14/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,127.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRRTX + ABBV for your $10,000?

TRRTX: 50%ABBV: 50%
100% ABBV50/50100% TRRTX
Portfolio after 10yr
$67.2K
Annual income
$13,297.65/yr
Blended yield
19.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TRRTX
Analyst Ratings
2
Hold
Consensus: Hold
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRRTX buys
0
ABBV buys
0
No recent congressional trades found for TRRTX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRRTXABBV
Forward yield5.95%3.12%
Annual dividend / share$0.69$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$29.6K$104.7K
Annual income after 10y$869.58$25,725.73
Total dividends collected$7.4K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: TRRTX vs ABBV ($10,000, DRIP)

YearTRRTX PortfolioTRRTX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,295$595.06$11,559$438.51$264.00ABBV
2$12,714$628.15$13,494$640.86$780.00ABBV
3$14,265$660.80$15,951$945.97$1.7KABBV
4$15,956$692.90$19,152$1,413.89$3.2KABBV
5$17,797$724.36$23,443$2,146.38$5.6KABBV
6$19,798$755.09$29,391$3,321.96$9.6KABBV
7$21,969$785.03$37,948$5,265.87$16.0KABBV
8$24,321$814.12$50,795$8,596.74$26.5KABBV
9$26,866$842.31$71,034$14,549.41$44.2KABBV
10$29,616$869.58$104,715$25,725.73$75.1KABBV

TRRTX vs ABBV: Complete Analysis 2026

TRRTXStock

The investment seeks the highest total return over time consistent with an emphasis on both capital growth and income. The fund pursues its objective by investing in a diversified portfolio of other T. Rowe Price stock and bond mutual funds that represent various asset classes and sectors. It is managed based on the specific retirement year (target date 2015) included in its name and assumes a retirement age of 65. The target date refers to the approximate year an investor in the fund would plan to retire and likely stop making new investments in the fund.

Full TRRTX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TRRTX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRRTX vs SCHDTRRTX vs JEPITRRTX vs OTRRTX vs KOTRRTX vs MAINTRRTX vs JNJTRRTX vs MRKTRRTX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.